Intraumbilical Oxytocin Versus Placental Cord Drainage in the Management of 3rd Stage of Labor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-30

Study Completion Date

2018-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to compare the effectiveness of intraumbilical oxytocin and placental cord drainage in the management of third stage of labor.

Does the use of intraumbilical vein oxytocin injection or the use of Placental cord drainage can cause a reduction of blood loss, Hb level drop, the length of the third stage of labor and the incidence of manual removal of the retained placenta during the third stage of labor in pregnant women after delivery of the infant?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prophylactic Use of Intraumbilical Vein Oxytocin Injection in The Management of Third Stage of Labor

NCT02680938

Postpartum Hemorrhage

UNKNOWN PHASE1

Placental Cord Drainage Versus no Placental Drainage in the Management of Third Stage of Labour

NCT03137810

Obstetric Delivery

UNKNOWN NA

Intraumbilical Vein Injection of Oxytocin in Routine Practice for Active Management of the Third Stage of Labor

NCT01094028

Labor

COMPLETED PHASE3

Cervical Traction vs. Active Management of 3rd Stage of Labor

NCT04747015

Post Partum Hemorrhage

UNKNOWN NA

Prophylactic Oxytocin Before Versus After Placental Delivery to Reduce Blood Loss in Vaginal Delivery

NCT03006380

Postpartum Hemorrhage

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study:

Study Design: A prospective randomized clinical trial. Study setting: The study will be conducted in Ain Shams University Maternity Hospital.

All pregnant women in the delivery ward will be submitted to:

1. Detailed complete history taking with special emphasis to maternal age, Parity, Maternal weight, as well as presence of any disease.
2. Clinical Examination:

a. General examination. b. Abdominal examination (Symphysis-fundal height) and pelvic examination.
3. Investigation

1. Ultrasound assessment to evaluate GA, fetal weight, AFI and Placental site.
2. Basal complete blood picture, urine analysis and random blood sugar.

The selected patients will fulfill the following criteria:

• Pregnant women between 18-35 years of age with normal pregnancy.

• A singleton fetus at a gestational age of 37 - 42 weeks in a cephalic presentation.

• Neonatal birth weight of 2500 to 4500 grams.

Exclusion criteria:

• Medical disorders and hypertensive disorders of pregnancy.

• Intrauterine fetal death.

• Known or suspected fetal anomalies.

• Oxytocin induction or Augmented cases.
* Obstetrical complications (bleeding, premature rupture of membranes).
* Previous CS or Previous Myomectomy.

Study population:

The present study will be conducted on 150 women recruited from the delivery ward of our hospital after they had received information on the purpose and course of the study from the medical investigator and had provided the written consent during routine prenatal visits , The 150 study participants will be divided into three groups using simple random distribution technique. After monitoring the duration of active phase and second stage of labor by following the partograph.

Randomization and Allocation concealment:

Randomization will be based on the sequence generation created by computer and the randomization tables will be kept with the study supervisor. Consenting patients fulfilling inclusion criteria will be randomized into one of the following 3 groups. Randomized allocation will be kept in opaque sealed envelopes, with enrollment numbers written on the envelopes. The envelopes will contain a card on with the designated study group will be written. After enrollment of the patients in the study, the envelopes marked with study number will be unsealed and the patients allocated to either groups:

• Group (A) "Study Group 1": In the labor room women in Group A (n = 50) receive intraumbilical vein injection oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.

• Group (B) "Study Group 2": The women in Group B (n = 50) have placental drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.

• Group (C) "Control Group": The women in Group C (n = 50) as a control group receive no intervention. Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.

Outcome:

Retained placenta is defined as a placenta that remained in the uterus for 30 minutes or more after delivery (Begley et al., 2014).
* 1ry outcome: Duration of the third stage of labor.
* 2ry outcome: Retained placenta, need for manual removal of placenta and the drop in Hb will be recorded.

Sample size calculation:

Sample size was calculated using PASS® version 11 program, sample size calculation was based on study carried out by (Güngördük et al., 2011). A preliminary power analysis was carried out to calculate the sample size using a formula: d = Δ/SD, where d is standardized difference, Δ is the smallest clinically significant difference and SD is standard deviation of the test group. Duration of 1.6 minutes was considered as the smallest clinically significant difference, and the SD (1.6 minutes) was selected the study performed by (Güngördük et al., 2011). Also, a standardized difference of 1.0 was obtained using nomogram. The power analysis suggested that a sample of 50 women in each group would provide a power of 95%, at 5% significance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postpartum Haemorrhage With Retained Placenta

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The present study will be conducted on 150 women recruited from the delivery ward of our hospital after they had received information on the purpose and course of the study from the medical investigator and had provided the written consent during routine prenatal visits , they will be randomly divided into:

* Group (A) "Study Group 1": (n = 50)
* Group (B) "Study Group 2": (n = 50)
* Group (C) "Control Group": (n = 50)

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Caregivers

Randomization will be based on the sequence generation created by computer and the randomization tables will be kept with the study supervisor. Consenting patients fulfilling inclusion criteria will be randomized into one of the following 3 groups. Randomized allocation will be kept in opaque sealed envelopes, with enrollment numbers written on the envelopes. The envelopes will contain a card on with the designated study group will be written. After enrollment of the patients in the study, the envelopes marked with study number will be unsealed and the patients allocated to either groups

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

• Group (A) "Study Group 1":

In the labor room women in Group A (n = 50):

* Clamping and cutting the placental cord after delivery of the baby.
* Immediate intraumbilical vein injection of Oxytocin (Syntocinon®) 20 units diluted in 20 ml of 0.9% saline solution

Group Type EXPERIMENTAL

Intraumbilical vein injection oxytocin

Intervention Type DRUG

intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.

• Group (B) "Study Group 2":

In the labor room women in Group B (n = 50):

* Clamping and cutting the placental cord after delivery of the baby.
* Immediate unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.

Group Type EXPERIMENTAL

placental cord drainage

Intervention Type PROCEDURE

placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.

• Group (C) "Control Group":

In the labor room women in Group C (n = 50):

* Clamping and cutting the placental cord after 2 minutes of delivery of the baby.
* Placenta will be delivered spontaneously after appearance of clinical signs of placental separation

Group Type ACTIVE_COMPARATOR

Expectant managment of 3rd stage of labour

Intervention Type PROCEDURE

Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intraumbilical vein injection oxytocin

intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.

Intervention Type DRUG

placental cord drainage

placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.

Intervention Type PROCEDURE

Expectant managment of 3rd stage of labour

Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women between 18-35 years of age with normal pregnancy.
* A singleton fetus at a gestational age of 37 - 42 weeks in a cephalic presentation.
* Neonatal birth weight of 2500 to 4500 grams.

Exclusion Criteria

* Medical disorders and hypertensive disorders of pregnancy.
* Intrauterine fetal death.
* Known or suspected fetal anomalies.
* Oxytocin induction or augmented cases.
* Obstetrical complications (bleeding, premature rupture of membranes).
* Previous CS or Previous Myomectomy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes